Data:AXA/2025/FY/Earnings release.json: Difference between revisions
Appearance
Content deleted Content added
Section records derived from the published summary page (47 sections) |
Section records derived from the published summary page (46 sections) |
||
| Line 26: | Line 26: | ||
"Year 2026" |
"Year 2026" |
||
], |
], |
||
"content": "* Paris |
"content": "* The announcement was made in Paris on February 26th, 2026 (Year 2026), at 6:45 am CET.\n\n== Full Year 2025 Earnings ==" |
||
}, |
}, |
||
{ |
{ |
||
| Line 47: | Line 47: | ||
"Underlying earnings per share" |
"Underlying earnings per share" |
||
], |
], |
||
"content": "* AXA reports record results with underlying EPS (Underlying earnings per share) growth at the top end of the target range.\n\n== Key FY25 highlights ==" |
"content": "* AXA reports record results with underlying EPS (Underlying earnings per share) growth at the top end of the target range.\n\n=== Key FY25 highlights ===" |
||
}, |
}, |
||
{ |
{ |
||
| Line 100: | Line 100: | ||
"Year 2026" |
"Year 2026" |
||
], |
], |
||
"content": "* Solvency II ratio: 224% at December 31, 2025, +9 points vs. FY24 (Full year 2024)\n* Solvency II ratio: 215% on January 1, 2026 (Year 2026), reflecting the end of the grandfathering period\n\n== Capital Management ==" |
"content": "* Solvency II ratio: 224% at December 31, 2025, +9 points vs. FY24 (Full year 2024)\n* Solvency II ratio: 215% on January 1, 2026 (Year 2026), reflecting the end of the grandfathering period\n\n=== Capital Management ===" |
||
}, |
}, |
||
{ |
{ |
||
| Line 126: | Line 126: | ||
"Year 2026" |
"Year 2026" |
||
], |
], |
||
"content": "* Dividend of EUR 2.32 per share, up +8% vs. FY24 (Full year 2024).\n* Launch of an annual share buyback program of up to EUR 1.25bn.\n* Completion of EUR 3.8bn additional share buyback related to AXA IM (AXA Investment Managers) disposal, executed between July 2, 2025, and January 20, 2026 (Year 2026).\n\n== Outlook ==" |
"content": "* Dividend of EUR 2.32 per share, up +8% vs. FY24 (Full year 2024).\n* Launch of an annual share buyback program of up to EUR 1.25bn.\n* Completion of EUR 3.8bn additional share buyback related to AXA IM (AXA Investment Managers) disposal, executed between July 2, 2025, and January 20, 2026 (Year 2026).\n\n=== Outlook ===" |
||
}, |
}, |
||
{ |
{ |
||
| Line 134: | Line 134: | ||
1 |
1 |
||
], |
], |
||
"heading": " |
"heading": "2026 outlook and strategic plan", |
||
"tags": [], |
"tags": [], |
||
"links": [ |
"links": [ |
||
| Line 149: | Line 149: | ||
"Year 2026" |
"Year 2026" |
||
], |
], |
||
"content": "* Underlying earnings per share growth for 2026 (Year 2026) expected at the upper end of the 6-8% plan target range.\n* Expected impact of Solvency II revision |
"content": "* Underlying earnings per share growth for 2026 (Year 2026) is expected to be at the upper end of the 6-8% plan target range.\n* Expected impact of Solvency II revision is +17 points.\n* AXA will present its new strategic plan for 2027-2029 on September 21, 2026." |
||
}, |
}, |
||
{ |
{ |
||
| Line 174: | Line 174: | ||
"Property \u0026 casualty" |
"Property \u0026 casualty" |
||
], |
], |
||
"content": "* AXA delivered +9% earnings growth in core businesses |
"content": "* In 2025, AXA delivered strong performance with +9% earnings growth in core businesses, excluding AXA IM (AXA Investment Managers).\n* Reserve prudence was enhanced following excellent results.\n* P\u0026C (Property \u0026 casualty) franchise posted stellar results, balancing price and volume with best-in-class margins, a lower expense ratio, and higher investment income.\n* AXA XL Insurance increased earnings with stable underlying margins.\n* Life \u0026 Health earnings rose by 7%.\n** Life earnings reflect early benefits of the strategy to rejuvenate the business.\n** Health grew by 17%, even after absorbing the adverse change on VAT treatment in Mexico.\n* Investments in automation and Artificial Intelligence are driving efficiency gains.\n* Solvency II ratio is at a very strong level.\n* These results demonstrate the earnings power of AXA's diversified franchise and reinforce confidence in generating sustainable, long-term value.\n* Thomas Buberl, CEO of AXA, thanked colleagues, agents, partners, and customers." |
||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr-c8", |
"id": "chq99br5nr-c8", |
||
"chunk": 8, |
"chunk": 8, |
||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
"content": "* The document contains key highlights in a press release.\n\n== FY25 key highlights ==" |
|||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
"pages": [ |
"pages": [ |
||
2 |
2 |
||
| Line 206: | Line 219: | ||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c10", |
||
"chunk": |
"chunk": 10, |
||
"pages": [ |
"pages": [ |
||
2 |
2 |
||
], |
], |
||
"heading": " |
"heading": "Gross written premiums and other revenues by business line", |
||
"tags": [], |
"tags": [], |
||
"links": [ |
"links": [ |
||
| Line 233: | Line 246: | ||
"Property \u0026 casualty" |
"Property \u0026 casualty" |
||
], |
], |
||
"content": "* Total gross written premiums and other revenues were up 6%.\n* |
"content": "* Total gross written premiums and other revenues were up +6%.\n* Growth was driven by:\n** Property \u0026 Casualty: +5%.\n*** Commercial lines: +4%, from higher volumes (notably at AXA XL Insurance) and favorable price effects across all geographies.\n*** Personal lines: +7%, driven by favorable price effects and strong growth in net new contracts (notably in France (AXA France), Europe (AXA Europe), Asia \u0026 EME-LATAM).\n*** AXA XL Reinsurance: +8%, supported by alternative capital.\n** Life \u0026 Health: +8%.\n*** Life premiums: +9%.\n**** Protection: +11%, from strong sales in Hong Kong, Switzerland, and Japan.\n**** Unit-Linked: +13%, from higher volumes across all geographies.\n**** G/A: +4%, from continued momentum in Italy and France.\n*** Health premiums: +5%, driven by price effects in all geographies.\n\n=== Earnings ===" |
||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c11", |
||
"chunk": |
"chunk": 11, |
||
"pages": [ |
"pages": [ |
||
2 |
2 |
||
| Line 266: | Line 279: | ||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c12", |
||
"chunk": |
"chunk": 12, |
||
"pages": [ |
"pages": [ |
||
2 |
2 |
||
| Line 282: | Line 295: | ||
"Underlying earnings" |
"Underlying earnings" |
||
], |
], |
||
"content": "* Net income increased by 26% to EUR 9.8bn.\n* This increase mainly reflects the rise in underlying earnings and significantly positive exceptional items, notably the gain from the sale of AXA IM (AXA Investment Managers).\n\n== Balance sheet ==" |
"content": "* Net income increased by 26% to EUR 9.8bn.\n* This increase mainly reflects the rise in underlying earnings and significantly positive exceptional items, notably the gain from the sale of AXA IM (AXA Investment Managers).\n\n=== Balance sheet ===" |
||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c13", |
||
"chunk": |
"chunk": 13, |
||
"pages": [ |
"pages": [ |
||
3 |
3 |
||
| Line 311: | Line 324: | ||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c14", |
||
"chunk": |
"chunk": 14, |
||
"pages": [ |
"pages": [ |
||
3 |
3 |
||
| Line 339: | Line 352: | ||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c15", |
||
"chunk": |
"chunk": 15, |
||
"pages": [ |
"pages": [ |
||
3 |
3 |
||
| Line 355: | Line 368: | ||
"Underlying earnings" |
"Underlying earnings" |
||
], |
], |
||
"content": "* Underlying return on equity was 16.0% as of December 31, 2025, up 0.8 points versus December 31, 2024, due to higher underlying earnings and lower shareholders' equity.\n* Debt gearing was 22.3% as of December 31, 2025, up 1.7 points versus December 31, 2024.\n* This increase was driven by lower shareholders' equity and CSM, and the issuance of Restricted Tier 1 and Tier 2 subordinated debt (EUR 3.5bn), partly offset by redemption of outstanding grandfathered Tier 1 debt (EUR -1.9bn).\n* The Group (AXA)'s debt gearing was in line with its 19-23% plan guidance for 2024-2026.\n* Cash at Holding amounted to EUR 5.6bn as of December 31, 2025, up EUR 1.6bn versus December 31, 2024.\n* This reflected organic cash remittance from subsidiaries of EUR 7.5bn, up EUR 0.4bn versus December 31, 2024.\n\n== Capital management and outlook ==\n\n== Capital management ==" |
"content": "* Underlying return on equity was 16.0% as of December 31, 2025, up 0.8 points versus December 31, 2024, due to higher underlying earnings and lower shareholders' equity.\n* Debt gearing was 22.3% as of December 31, 2025, up 1.7 points versus December 31, 2024.\n* This increase was driven by lower shareholders' equity and CSM, and the issuance of Restricted Tier 1 and Tier 2 subordinated debt (EUR 3.5bn), partly offset by redemption of outstanding grandfathered Tier 1 debt (EUR -1.9bn).\n* The Group (AXA)'s debt gearing was in line with its 19-23% plan guidance for 2024-2026.\n* Cash at Holding amounted to EUR 5.6bn as of December 31, 2025, up EUR 1.6bn versus December 31, 2024.\n* This reflected organic cash remittance from subsidiaries of EUR 7.5bn, up EUR 0.4bn versus December 31, 2024.\n\n== Capital management and outlook ==\n\n=== Capital management ===" |
||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c16", |
||
"chunk": |
"chunk": 16, |
||
"pages": [ |
"pages": [ |
||
4 |
4 |
||
| Line 381: | Line 394: | ||
"Year 2026" |
"Year 2026" |
||
], |
], |
||
"content": "* A dividend of EUR 2.32 per share (+8% versus FY24 (Full year 2024)) will be proposed at the Shareholders' Annual General Meeting on April 30, 2026 (Year 2026).\n* The dividend is expected to be paid on May 13, 2026, with an ex-dividend date on May 11, 2026.\n* AXA's Board of Directors approved on February 25, 2026, the launch of an annual share buyback program for up to EUR 1.25bn.\n* The share buyback program will be executed in accordance with the terms of the applicable Shareholders' Annual General Meeting authorization.\n* AXA intends to cancel all shares repurchased pursuant to this share buyback program.\n* The share buyback program is expected to commence as soon as reasonably practicable, subject to market conditions, and to be completed by year-end.\n\n== Outlook ==" |
"content": "* A dividend of EUR 2.32 per share (+8% versus FY24 (Full year 2024)) will be proposed at the Shareholders' Annual General Meeting on April 30, 2026 (Year 2026).\n* The dividend is expected to be paid on May 13, 2026, with an ex-dividend date on May 11, 2026.\n* AXA's Board of Directors approved on February 25, 2026, the launch of an annual share buyback program for up to EUR 1.25bn.\n* The share buyback program will be executed in accordance with the terms of the applicable Shareholders' Annual General Meeting authorization.\n* AXA intends to cancel all shares repurchased pursuant to this share buyback program.\n* The share buyback program is expected to commence as soon as reasonably practicable, subject to market conditions, and to be completed by year-end.\n\n=== Outlook ===" |
||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c17", |
||
"chunk": |
"chunk": 17, |
||
"pages": [ |
"pages": [ |
||
4 |
4 |
||
| Line 409: | Line 422: | ||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c18", |
||
"chunk": |
"chunk": 18, |
||
"pages": [ |
"pages": [ |
||
4 |
4 |
||
| Line 437: | Line 450: | ||
"Year 2026" |
"Year 2026" |
||
], |
], |
||
"content": "* Holdings results: expected to remain similar in 2026 (Year 2026) as in 2025.\n* Management believes AXA is on track to deliver main financial targets of the 'Unlock the Future' plan, assuming current operating conditions persist and following strong 2025 operating performance.\n* Underlying earnings per share growth: expected at the upper end of the 6-8% CAGR target range for both 2023-2026E and for 2026.\n* Underlying return on equity: expected between 14% and 16% between 2024 and 2026E.\n* Cumulative organic cash upstream: expected in excess of EUR 21bn for 2024-2026E.\n* Capital management policy: Group (AXA) targets a total payout ratio of 75%.\n* Dividend payout ratio: 60%.\n* Annual share buybacks: additional 15%.\n* Proposed dividend per share: expected to be at least equal to the prior year's dividend per share.\n\n |
"content": "* Holdings results: expected to remain similar in 2026 (Year 2026) as in 2025.\n* Management believes AXA is on track to deliver main financial targets of the 'Unlock the Future' plan, assuming current operating conditions persist and following strong 2025 operating performance.\n* Underlying earnings per share growth: expected at the upper end of the 6-8% CAGR target range for both 2023-2026E and for 2026.\n* Underlying return on equity: expected between 14% and 16% between 2024 and 2026E.\n* Cumulative organic cash upstream: expected in excess of EUR 21bn for 2024-2026E.\n* Capital management policy: Group (AXA) targets a total payout ratio of 75%.\n* Dividend payout ratio: 60%.\n* Annual share buybacks: additional 15%.\n* Proposed dividend per share: expected to be at least equal to the prior year's dividend per share.\n\n== Property \u0026 Casualty ==" |
||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c19", |
||
"chunk": |
"chunk": 19, |
||
"pages": [ |
"pages": [ |
||
5 |
5 |
||
| Line 454: | Line 467: | ||
"Other revenue", |
"Other revenue", |
||
"AXA XL", |
"AXA XL", |
||
"Underlying earnings" |
"Underlying earnings", |
||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
], |
|||
"content": "**Key figures – Property \u0026 Casualty (Property \u0026 casualty)**\n\n| in Euro billion | FY24 (Full year 2024) | FY25 (Full year 2025) | Change on a comparable basis | FY25 Price effect(12) (in %) |\n| --- | --- | --- | --- | --- |\n| Gross written premiums and other revenues | 56.5 | 58.0 | +5% | +2.9% |\n| o/w Commercial lines(11) | 34.9 | 35.8 | +4% | +1.9% |\n| o/w Personal lines | 19.1 | 19.7 | +7% | +5.2% |\n| o/w AXA XL Reinsurance | 2.5 | 2.6 | +8% | +0.3% |\n\n| in Euro million | FY24 | FY25 | Change at constant Forex |\n| --- | --- | --- | --- |\n| All-Year Combined ratio | 91.0% | 90.6% | -0.3 pt |\n| Underlying earnings | 5,510 | 5,872 | +9% |" |
|||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
], |
|||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
"Gross written premiums \u0026 other revenues", |
"Gross written premiums \u0026 other revenues", |
||
| ⚫ | |||
"AXA Asia, Africa \u0026 EME-LATAM", |
"AXA Asia, Africa \u0026 EME-LATAM", |
||
"AXA France", |
"AXA France", |
||
| ⚫ | |||
"AXA Europe" |
"AXA Europe" |
||
], |
], |
||
| Line 491: | Line 481: | ||
"AXA France", |
"AXA France", |
||
"AXA XL", |
"AXA XL", |
||
| ⚫ | |||
"Gross written premiums \u0026 other revenues" |
|||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
], |
], |
||
"content": "* Gross written premiums \u0026 other revenues |
"content": "**Key figures – Property \u0026 Casualty (Property \u0026 casualty)**\n\n| in Euro billion | FY24 (Full year 2024) | FY25 (Full year 2025) | Change on a comparable basis | FY25 Price effect(12) (in %) |\n| --- | --- | --- | --- | --- |\n| Gross written premiums and other revenues | 56.5 | 58.0 | +5% | +2.9% |\n| o/w Commercial lines(11) | 34.9 | 35.8 | +4% | +1.9% |\n| o/w Personal lines | 19.1 | 19.7 | +7% | +5.2% |\n| o/w AXA XL Reinsurance | 2.5 | 2.6 | +8% | +0.3% |\n**Earnings (in Euro million, unless otherwise noted)**\n\n| | FY24 | FY25 | Change at constant Forex |\n| --- | --- | --- | --- |\n| All-Year Combined ratio | 91.0% | 90.6% | -0.3 pt |\n| Underlying earnings | 5,510 | 5,872 | +9% |\nGross written premiums \u0026 other revenues were up 5% to Euro 58.0 billion.\n* Commercial lines grew by 4% to Euro 35.8 billion, driven by:\n* AXA XL Insurance (+3%) from growth in lines with attractive margins, including in Property, and in Casualty from both favorable price effects and higher volumes, partly offset by lower pricing and volumes in Financial lines;\n* Asia, Africa \u0026 EME-LATAM (AXA Asia, Africa \u0026 EME-LATAM) (+13%) mainly driven by Türkiye from higher average premiums, along with favorable volume and price effects in Mexico; and\n* France (AXA France) (+6%) from favorable price effects in all lines of business (Business mix) and higher volumes.\n* Personal lines grew by 7% to Euro 19.7 billion, driven by:\n* Europe (AXA Europe) (+5%) from favorable price effects across geographies, except in UK \u0026 Ireland Motor, where pricing softened following strong repricing in 2024;\n* Asia, Africa \u0026 EME-LATAM (+14%) driven by Türkiye from higher average premiums and volumes; and\n* France (+9%) with strong volume growth in all lines of business, both from direct business and proprietary agent networks, combined with favorable price effects in Motor.\n* AXA XL Reinsurance grew by 8% to Euro 2.6 billion, driven by growth supported by alternative capital and favorable price effects in Casualty partly offset by a softening in other lines.\nThe all-year combined ratio improved by 0.3 point to 90.6%, mainly driven by:\n* Lower undiscounted current year loss ratio excluding natural catastrophe (-0.3 point) from further margin expansion in (i) Commercial lines (-0.5 point), driven by the SME \u0026 mid-market business (-0.9 point) in a favorable pricing environment, while margins at AXA XL Insurance were stable at attractive levels (+0.1 point), as well as in (ii) Personal lines (-0.4 point) in a conducive pricing environment;\n* Lower expense ratio (-0.3 point) primarily from lower non-commission expense ratio reflecting efficiency gains; and\n* Lower natural catastrophe charges (-0.4 point to 3.4%) more than offset by lower prior years' reserve development (+0.7 point at -1.1%)." |
||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr-c20", |
"id": "chq99br5nr-c20", |
||
"chunk": 20, |
"chunk": 20, |
||
"pages": [ |
|||
5 |
|||
], |
|||
| ⚫ | |||
"tags": [], |
|||
"links": [ |
|||
"AXA XL" |
|||
], |
|||
"data_items": [], |
|||
"effective_tags": [ |
|||
"AXA", |
|||
"AXA XL" |
|||
], |
|||
"content": "* All-year combined ratio improved by 0.3pts to 90.6%.\n* Driven by lower undiscounted current year loss ratio excluding natural catastrophe (-0.3pts) from margin expansion in Commercial lines (-0.5pts), specifically SME \u0026 mid-market business (-0.9pts) in a favorable pricing environment, while AXA XL Insurance margins were stable (+0.1pts).\n* Also driven by lower undiscounted current year loss ratio in Personal lines (-0.4pts) in a conducive pricing environment.\n* Lower expense ratio (-0.3pts) primarily from lower non-commission expense ratio reflecting efficiency gains.\n* Lower natural catastrophe charges (-0.4pts to 3.4%) more than offset by lower prior years' reserve development (+0.7pts at -1.1%)." |
|||
}, |
|||
{ |
|||
"id": "chq99br5nr-c21", |
|||
"chunk": 21, |
|||
"pages": [ |
"pages": [ |
||
6 |
6 |
||
| Line 530: | Line 509: | ||
"Underlying earnings" |
"Underlying earnings" |
||
], |
], |
||
"content": "* P\u0026C (Property \u0026 casualty) underlying earnings +9% to EUR 5.9bn |
"content": "* P\u0026C (Property \u0026 casualty) underlying earnings: +9% to EUR 5.9bn\n* Driven by:\n** Increase in technical result: +EUR 0.5bn, reflecting strong volume growth and improved technical margin\n** Higher financial result: +EUR 0.2bn, due to higher volumes and reinvestment yields on fixed income assets, offsetting increased unwind of discount of claims reserves\n* Partly offset by:\n** Higher income taxes: -EUR 0.2bn, mainly due to higher pre-tax underlying earnings\n\n== Life \u0026 Health ==" |
||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c21", |
||
"chunk": |
"chunk": 21, |
||
"pages": [ |
"pages": [ |
||
6 |
6 |
||
| Line 555: | Line 534: | ||
"Underlying earnings" |
"Underlying earnings" |
||
], |
], |
||
"content": "**Key figures – Life \u0026 Health (Life \u0026 health)**\n\n| in Euro billion | FY24 (Full year 2024) | FY25 (Full year 2025) | Change on a comparable basis |\n| --- | --- | --- | --- |\n| Gross written premiums \u0026 other revenues (Gross written premiums \u0026 other revenues) | 52.0 | 56.5 | +8% |\n| o/w Life | 34.5 | 37.5 | +9% |\n| o/w Health | 17.5 | 19.0 | +5% |\n| PVEP(1,21) | 50.9 | 49.4 | -2% |\n| NB CSM(1,21) | 2.2 | 2.2 | +3% |\n| NBV (post-tax)(1,21) | 2.3 | 2.2 | 0% |\n| NBV margin(1,21) | 4.4% | 4.5% | +0.1 pt |\n| Net flows(21) | +1.5 | +5.4 | |\n\n| in Euro million | FY24 | FY25 | Change at constant forex |\n| --- | --- | --- | --- |\n| Underlying earnings | 3,323 | 3,501 | +7% |\n| o/w Life | 2,636 | 2,715 | +4% |\n| o/w Health | 687 | 787 | +17% |\n\n |
"content": "**Key figures – Life \u0026 Health (Life \u0026 health)**\n\n| in Euro billion | FY24 (Full year 2024) | FY25 (Full year 2025) | Change on a comparable basis |\n| --- | --- | --- | --- |\n| Gross written premiums \u0026 other revenues (Gross written premiums \u0026 other revenues) | 52.0 | 56.5 | +8% |\n| o/w Life | 34.5 | 37.5 | +9% |\n| o/w Health | 17.5 | 19.0 | +5% |\n| PVEP(1,21) | 50.9 | 49.4 | -2% |\n| NB CSM(1,21) | 2.2 | 2.2 | +3% |\n| NBV (post-tax)(1,21) | 2.3 | 2.2 | 0% |\n| NBV margin(1,21) | 4.4% | 4.5% | +0.1 pt |\n| Net flows(21) | +1.5 | +5.4 | |\n\n| in Euro million | FY24 | FY25 | Change at constant forex |\n| --- | --- | --- | --- |\n| Underlying earnings | 3,323 | 3,501 | +7% |\n| o/w Life | 2,636 | 2,715 | +4% |\n| o/w Health | 687 | 787 | +17% |\n\n=== Gross written premiums \u0026 other revenues were up 8% to Euro 56.5 billion. ===" |
||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c22", |
||
"chunk": |
"chunk": 22, |
||
"pages": [ |
"pages": [ |
||
6 |
6 |
||
], |
], |
||
"heading": "Life \u0026 Health |
"heading": "Life \u0026 Health gross written premiums", |
||
"tags": [], |
"tags": [], |
||
"links": [ |
"links": [ |
||
| Line 576: | Line 555: | ||
"Gross written premiums" |
"Gross written premiums" |
||
], |
], |
||
"content": "* Life GWP (Gross written premiums) grew |
"content": "* Life GWP (Gross written premiums) grew +9% to EUR 37.5bn, mainly from:\n** Unit-Linked: +13% driven by successful sales initiatives across all geographies\n** G/A: +4%, notably in France (AXA France) (+4%), and elevated sales of a capital-light product in Italy\n** G/A was partly offset by non-repeat of elevated sales of a single premium whole-life product in Japan, and lower sales in Hong Kong\n** Protection: +11%, notably from a commercial campaign on a Protection with G/A product in Hong Kong and continued good sales of Protection with Unit-Linked product in Japan and Switzerland\n* Health GWP grew +5% to EUR 19.0bn, driven by favorable price effects in both Group (AXA) and Individual businesses across most geographies\n* Health GWP was partly offset by lower volumes" |
||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c23", |
||
"chunk": |
"chunk": 23, |
||
"pages": [ |
"pages": [ |
||
| ⚫ | |||
7 |
7 |
||
], |
], |
||
| Line 594: | Line 574: | ||
"AXA France" |
"AXA France" |
||
], |
], |
||
"content": "* Present value of expected premiums (PVEP) decreased |
"content": "* Present value of expected premiums (PVEP) decreased -2% to EUR 49.4bn, driven by:\n** Life: +1%, from higher volumes in Hong Kong, France (AXA France), and Switzerland\n** Life was partly offset by the impact of higher interest rates on discounting of future premiums\n** Health: -12%, mainly from the impact of higher interest rates on discounting of future premiums, and lower volumes in France following underwriting and pruning actions" |
||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c24", |
||
"chunk": |
"chunk": 24, |
||
"pages": [ |
"pages": [ |
||
7 |
7 |
||
| Line 612: | Line 592: | ||
"AXA France" |
"AXA France" |
||
], |
], |
||
"content": "* NB CSM increased |
"content": "* NB CSM increased +3% to EUR 2.2bn, driven by strong sales in Savings and Protection\n* NB CSM was partly offset by the impact of higher interest rates on discounting of future profits\n* NBV (post-tax) was stable at EUR 2.2bn\n* NBV growth was offset by the decrease in the contribution of short-term multinational business in France (AXA France)\n* NBV margin (post tax) increased +0.1pt to 4.5%" |
||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c25", |
||
"chunk": |
"chunk": 25, |
||
"pages": [ |
"pages": [ |
||
7 |
7 |
||
| Line 630: | Line 610: | ||
"AXA France" |
"AXA France" |
||
], |
], |
||
"content": "* Net flows were EUR +5.4bn |
"content": "* Net flows were EUR +5.4bn (prior: EUR +1.5bn in 2024), driven by:\n** Protection: EUR +4.9bn, mainly in Hong Kong, Japan, and France (AXA France)\n** Health: EUR +2.7bn, mainly in Germany, Japan, and France\n** Unit-Linked: EUR +1.5bn, primarily in France\n** Partly offset by G/A Savings: EUR -3.7bn\n** Inflows in G/A capital-light (EUR +1.2bn) were more than offset by outflows in traditional G/A Savings (EUR -5.0bn)" |
||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c26", |
||
"chunk": |
"chunk": 26, |
||
"pages": [ |
"pages": [ |
||
7 |
7 |
||
| Line 653: | Line 633: | ||
"Underlying earnings" |
"Underlying earnings" |
||
], |
], |
||
"content": "* Life \u0026 Health underlying earnings increased |
"content": "* Life \u0026 Health underlying earnings increased +7% to EUR 3.5bn, driven by:\n** Long-term technical result: EUR +0.2bn, driven by an increase in CSM release, following both growth in reserves and better margins in the long-term business\n** Short-term technical result: EUR +0.1bn, driven by the expansion of technical margin reflecting pricing, underwriting and claims management actions to strengthen technical excellence across geographies\n** Short-term technical result more than offset the impact of a legislative change on the recoverability of value added tax in Mexico (EUR -0.1bn)\n** Lower income taxes: EUR +0.1bn, reflecting favorable tax effects mainly in Germany, France (AXA France) and Mexico\n** Lower contribution from affiliates, notably ICBC-AXA, and improved results at AXA MPS that resulted in an increase in earnings of minority shareholders\n\n== Holdings ==" |
||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c27", |
||
"chunk": |
"chunk": 27, |
||
"pages": [ |
"pages": [ |
||
7 |
7 |
||
| Line 673: | Line 653: | ||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c28", |
||
"chunk": |
"chunk": 28, |
||
"pages": [ |
"pages": [ |
||
8 |
8 |
||
| Line 690: | Line 670: | ||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c29", |
||
"chunk": |
"chunk": 29, |
||
"pages": [ |
"pages": [ |
||
8, |
8, |
||
| Line 716: | Line 696: | ||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c30", |
||
"chunk": |
"chunk": 30, |
||
"pages": [ |
"pages": [ |
||
10 |
10 |
||
| Line 749: | Line 729: | ||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c31", |
||
"chunk": |
"chunk": 31, |
||
"pages": [ |
"pages": [ |
||
10 |
10 |
||
| Line 768: | Line 748: | ||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c32", |
||
"chunk": |
"chunk": 32, |
||
"pages": [ |
"pages": [ |
||
11 |
11 |
||
| Line 781: | Line 761: | ||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c33", |
||
"chunk": |
"chunk": 33, |
||
"pages": [ |
"pages": [ |
||
11 |
11 |
||
| Line 794: | Line 774: | ||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c34", |
||
"chunk": |
"chunk": 34, |
||
"pages": [ |
"pages": [ |
||
11 |
11 |
||
| Line 813: | Line 793: | ||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c35", |
||
"chunk": |
"chunk": 35, |
||
"pages": [ |
"pages": [ |
||
12 |
12 |
||
], |
], |
||
"heading": "AXA Group overview |
"heading": "AXA Group overview", |
||
"tags": [], |
"tags": [], |
||
"links": [ |
"links": [ |
||
| Line 829: | Line 809: | ||
"Underlying earnings" |
"Underlying earnings" |
||
], |
], |
||
"content": "* AXA Group (AXA) is a worldwide leader in insurance with 156,000 employees serving over 92 million clients in 52 countries.\n* In 2025, IFRS17 revenues amounted to EUR 115.5bn.\n* In 2025, IFRS17 underlying earnings amounted to EUR 8.4bn.\n* The AXA ordinary share is listed on compartment A of Euronext Paris under ticker symbol CS (ISN FR 0000120628 – Bloomberg: CS FP – Reuters: AXAF.PA).\n* AXA’s American Depository Share is quoted on the OTC QX platform under ticker symbol AXAHY.\n* AXA Group is included in main international SRI indexes, including Dow Jones Sustainability Index (DJSI) and FTSE4GOOD.\n* AXA is a founding member of the UN Environment Programme’s Finance Initiative (UNEP FI) Principles for Sustainable Insurance |
"content": "* AXA Group (AXA) is a worldwide leader in insurance with 156,000 employees serving over 92 million clients in 52 countries.\n* In 2025, IFRS17 revenues amounted to EUR 115.5bn.\n* In 2025, IFRS17 underlying earnings amounted to EUR 8.4bn.\n* The AXA ordinary share is listed on compartment A of Euronext Paris under ticker symbol CS (ISN FR 0000120628 – Bloomberg: CS FP – Reuters: AXAF.PA).\n* AXA’s American Depository Share is quoted on the OTC QX platform under ticker symbol AXAHY.\n* AXA Group is included in main international SRI indexes, including Dow Jones Sustainability Index (DJSI) and FTSE4GOOD.\n* AXA is a founding member of the UN Environment Programme’s Finance Initiative (UNEP FI) Principles for Sustainable Insurance and a signatory of the UN Principles for Responsible Investment.\n* Press release and regulated information are available on the AXA Group website (axa.com)." |
||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c36", |
||
"chunk": |
"chunk": 36, |
||
"pages": [ |
"pages": [ |
||
12 |
12 |
||
| Line 842: | Line 822: | ||
"data_items": [], |
"data_items": [], |
||
"effective_tags": [], |
"effective_tags": [], |
||
"content": "* Investor Relations contact: +33.1.40.75.48.42 |
"content": "* Investor Relations contact: +33.1.40.75.48.42, investor.relations@axa.com.\n* Individual Shareholder Relations contact: +33.1.40.75.48.43.\n* Media Relations contact: +33.1.40.75.46.74, ziad.gebran@axa.com, ahlem.girard@axa.com, sylwia.tulak@axa.com.\n* Corporate Responsibility strategy information available at axa.com/en/about-us/strategy-commitments.\n* SRI ratings information available at axa.com/en/investor/sri-ratings-ethical-indexes.\n\n== Important legal information and cautionary statements concerning forward-looking statements and the use of non-gaap financial measures ==" |
||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c37", |
||
"chunk": |
"chunk": 37, |
||
"pages": [ |
"pages": [ |
||
12 |
12 |
||
| Line 868: | Line 848: | ||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c38", |
||
"chunk": |
"chunk": 38, |
||
"pages": [ |
"pages": [ |
||
13 |
13 |
||
| Line 908: | Line 888: | ||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c39", |
||
"chunk": |
"chunk": 39, |
||
"pages": [ |
"pages": [ |
||
14 |
14 |
||
| Line 946: | Line 926: | ||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c40", |
||
"chunk": |
"chunk": 40, |
||
"pages": [ |
"pages": [ |
||
15 |
15 |
||
| Line 973: | Line 953: | ||
"Property \u0026 casualty" |
"Property \u0026 casualty" |
||
], |
], |
||
"content": "**Total P\u0026C (Property \u0026 casualty) by Commercial lines, Personal lines, and AXA XL Reinsurance**\n\n| in Euro million | Commercial lines Total Commercial | Commercial lines Change(i) | Personal lines Personal Motor | Personal lines Change(i) | Personal lines Personal Non-Motor | Personal lines Change(i) | AXA XL Reinsurance Total Personal | AXA XL Reinsurance Change(i) | AXA XL Reinsurance Total Reinsurance | AXA XL Reinsurance Change(i) | Total P\u0026C FY25 (Full year 2025) | Total P\u0026C Change(i) |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| France (AXA France) | 5,077 | +6% | 2,693 | +9% | 1,877 | +10% | 4,570 | +9% | - | - | 9,648 | +7% |\n| Europe (AXA Europe) | 9,179 | +1% | 7,434 | +6% | 4,644 | +5% | 12,078 | +5% | - | - | 21,257 | +4% |\n| AXA XL | 16,604 | +3% | - | - | - | - | - | - | 2,555 | +8% | 19,159 | +4% |\n| Asia, Africa \u0026 EME-LATAM (AXA Asia, Africa \u0026 EME-LATAM) | 3,193 | +13% | 2,315 | +14% | 749 | +12% | 3,064 | +14% | - | - | 6,257 | +13% |\n| Transversal | 1,718 | -1% | - | - | - | - | - | - | - | - | 1,718 | -1% |\n| Total | 35,771 | +4% | 12,443 | +8% | 7,269 | +7% | 19,712 | +7% | 2,555 | +8% | 58,038 | +5% |\n\n(i) Changes are at comparable basis (constant forex, scope and methodology)\n\n| | FY24 (Full year 2024)(i) | FY25(ii) |\n| --- | --- | --- |\n| EUR | 2.8% | 2.6% |\n| USD | 4.4% | 4.2% |\n| JPY | 0.4% | 1.0% |\n| GBP | 4.3% | 4.3% |\n| CHF | 0.8% | 0.2% |\n| HKD | 3.7% | 3.2% |\n\n(i) Calculated as monthly average from January 2024 to December 2024\n(ii) Average of monthly opening discount rates of 2025\n\n== Appendix 4: Property \u0026 Casualty – price effect \u0026 2026 market pricing trends ==" |
"content": "**Total P\u0026C (Property \u0026 casualty) by Commercial lines, Personal lines, and AXA XL Reinsurance**\n\n| in Euro million | Commercial lines Total Commercial | Commercial lines Change(i) | Personal lines Personal Motor | Personal lines Change(i) | Personal lines Personal Non-Motor | Personal lines Change(i) | AXA XL Reinsurance Total Personal | AXA XL Reinsurance Change(i) | AXA XL Reinsurance Total Reinsurance | AXA XL Reinsurance Change(i) | Total P\u0026C FY25 (Full year 2025) | Total P\u0026C Change(i) |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| France (AXA France) | 5,077 | +6% | 2,693 | +9% | 1,877 | +10% | 4,570 | +9% | - | - | 9,648 | +7% |\n| Europe (AXA Europe) | 9,179 | +1% | 7,434 | +6% | 4,644 | +5% | 12,078 | +5% | - | - | 21,257 | +4% |\n| AXA XL | 16,604 | +3% | - | - | - | - | - | - | 2,555 | +8% | 19,159 | +4% |\n| Asia, Africa \u0026 EME-LATAM (AXA Asia, Africa \u0026 EME-LATAM) | 3,193 | +13% | 2,315 | +14% | 749 | +12% | 3,064 | +14% | - | - | 6,257 | +13% |\n| Transversal | 1,718 | -1% | - | - | - | - | - | - | - | - | 1,718 | -1% |\n| Total | 35,771 | +4% | 12,443 | +8% | 7,269 | +7% | 19,712 | +7% | 2,555 | +8% | 58,038 | +5% |\n\n(i) Changes are at comparable basis (constant forex, scope and methodology)\n\n| | FY24 (Full year 2024)(i) | FY25(ii) |\n| --- | --- | --- |\n| EUR | 2.8% | 2.6% |\n| USD | 4.4% | 4.2% |\n| JPY | 0.4% | 1.0% |\n| GBP | 4.3% | 4.3% |\n| CHF | 0.8% | 0.2% |\n| HKD | 3.7% | 3.2% |\n\n(i) Calculated as monthly average from January 2024 to December 2024\n(ii) Average of monthly opening discount rates of 2025\n\n== Appendix 4: Property \u0026 Casualty – price effect \u0026 2026 market pricing trends ==\n\n=== P\u0026C: Price effects i by country and business line ===" |
||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c41", |
||
"chunk": |
"chunk": 41, |
||
"pages": [ |
"pages": [ |
||
16 |
16 |
||
| Line 1,008: | Line 988: | ||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c42", |
||
"chunk": |
"chunk": 42, |
||
"pages": [ |
"pages": [ |
||
17 |
17 |
||
| Line 1,038: | Line 1,018: | ||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c43", |
||
"chunk": |
"chunk": 43, |
||
"pages": [ |
"pages": [ |
||
18 |
18 |
||
| Line 1,062: | Line 1,042: | ||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c44", |
||
"chunk": |
"chunk": 44, |
||
"pages": [ |
"pages": [ |
||
19 |
19 |
||
| Line 1,085: | Line 1,065: | ||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c45", |
||
"chunk": |
"chunk": 45, |
||
"pages": [ |
"pages": [ |
||
20 |
20 |
||
], |
], |
||
"heading": "Main transactions |
"heading": "Main transactions", |
||
"tags": [], |
"tags": [], |
||
"links": [ |
"links": [ |
||
| ⚫ | |||
"AXA", |
"AXA", |
||
| ⚫ | |||
"AXA Investment Managers" |
"AXA Investment Managers" |
||
], |
], |
||
| Line 1,104: | Line 1,084: | ||
"Share buyback" |
"Share buyback" |
||
], |
], |
||
"content": "* |
"content": "* AXA announced the execution of a share repurchase (Share buyback) agreement for its share buyback program of up to EUR 1.2bn (February 28, 2025).\n* AXA announced the completion of the acquisition of Nobis Group (AXA) in Italy (April 1, 2025).\n* AXA announced the placement of EUR 1bn Restricted Tier 1 Notes and EUR 1bn Tier 2 Notes (May 28, 2025).\n* AXA announced the execution of a share repurchase agreement for its Shareplan and certain stock-based compensation (June 2, 2025).\n* AXA announced the completion of the sale of AXA Investment Managers to BNP Paribas (July 1, 2025).\n* AXA announced the execution of a share repurchase agreement of up to EUR 3.8bn following the sale of AXA IM (AXA Investment Managers) (July 1, 2025).\n* AXA announced the acquisition of Prima, a direct insurance player in Italy (August 1, 2025).\n* AXA announced the launch (September 10, 2025) and successful completion (December 3, 2025) of the 2025 employee share offering program (Shareplan 2025).\n* AXA announced the placement of EUR 750m Restricted Tier 1 Notes and EUR 750m Tier 2 Notes (October 14, 2025).\n* AXA announced the completion of the acquisition of a majority stake in Prima in Italy (November 28, 2025).\n\n=== Next main investor events ===" |
||
}, |
}, |
||
{ |
{ |
||
"id": "chq99br5nr- |
"id": "chq99br5nr-c46", |
||
"chunk": |
"chunk": 46, |
||
"pages": [ |
"pages": [ |
||
20 |
20 |
||
], |
], |
||
"heading": "Investor |
"heading": "Investor events", |
||
"tags": [], |
"tags": [], |
||
"links": [ |
"links": [ |
||
| Line 1,125: | Line 1,105: | ||
"Year 2026" |
"Year 2026" |
||
], |
], |
||
"content": "* 2026 (Year 2026) |
"content": "* 2026 (Year 2026) Shareholder's Annual General Meeting: April 30, 2026\n* First quarter 2026 Activity Indicators: May 5, 2026\n* HY26 Earnings Release: July 31, 2026\n* AXA Investor Day: September 21, 2026" |
||
} |
} |
||
], |
], |
||
Revision as of 23:19, 25 July 2026
| doc_id | "chq99br5nr" | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| document |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| sections |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| title | "AXA/2025/FY/Earnings release" | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| source_url | "https://www-axa-com.cdn.prismic.io/www-axa-com/aZ_Ib8FoBIGEg123_AXA_PR_20260226.pdf" |